Category: Federal Forum Posters
Purpose: oral anticoagulation, either in the form of Vitk antagonist or direct oral anticoagulants (DOAC), is the recommended therapy for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The major safety concern while receiving oral anticoagulation is hemorrhage, and recurrent thromboses. This Study aim to determine risk factors associated with recurrent thrombi using DOACS.
Methods: this pilot, retrospective case-control analysis was conducted at GLWACH (internal medication clinic only) . Patients with an active outpatient order for Apixaban, Rivaroxaban, or Dabigatran for at least 360 days with a medication possession ratio of at least 80 percent, plus documented of hospitalization of thrombi event. a recurrent thromboses event is defined as either an admission or discharge associated any diagnosis code for recurrent thrombosis The chosen variable of evaluation were: age 40 or older, kidney dysfunction (ESRD), gender, BMI more than 35 kg/m2, Hypoalbuminemia, and liver disease (Child - Pugh Score Class B and C).
Results: a total of 12 recurrent thrombi event was discover. Baseline demographic information was evaluated across the type of DOAC the patient received. In general, there were not significant differences amongst the various DOACS. Univariate analysis identified the following is significant possible predictors: BMI is equal to or higher of 40 kg/m2
Conclusion: This is the first independent trial to analyze the predictive role of various factors on recurrent thrombosis events in patients receiving a DOAC. BMI at 40 kg/m2or greater was associated with recurrent thrombosis event in patients receiving a DOAC. The results of this analysis may aid in identification of factors associated with higher thrombi rates in patients receiving DOACS